key: cord-0285026-5rkxs2w3
authors: Solomon, J.; Danoff, S.; Woodhead, F.; Hurwitz, S.; Maurer, R.; Glaspole, I.; Dellaripa, P. F.; Gooptu, B.; Vassallo, R.; Cox, P. G.; Flaherty, K. R.; Adamali, H.; Gibbons, M. A.; Troy, L.; Forrest, I.; Lasky, J. A.; Spencer, L. G.; Golden, J.; Scholand, M. B.; Chaudhuri, N.; Perrella, M. A.; Lynch, D.; Chambers, D. C.; Kolb, M.; Spino, C.; Raghu, G.; Goldberg, H.; Rosas, I. O.; Investigators, TRAIL1
title: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease
date: 2022-04-01
journal: nan
DOI: 10.1101/2022.04.01.22273270
sha: 19faad2b2f26b25c44e378a3805bba0777f73fa6
doc_id: 285026
cord_uid: 5rkxs2w3

Background Interstitial lung disease (ILD) is a known complication of rheumatoid arthritis (RA) with a lifetime risk in any individual of 7.7%. The TRAIL1 trial was a randomized, double-blinded, placebo-controlled, phase 2 study of safety, tolerability, and efficacy of pirfenidone for the treatment of patients with RA-ILD. Methods The TRAIL1 was a phase 2 trial intended to enroll 270 adult patients (18 to 85 years) with established RA-ILD at 33 sites in 4 countries. Patients were randomly assigned (1:1) to 2,403 mg oral pirfenidone or placebo daily. The primary endpoint was the incidence of the composite endpoint of decline from baseline in percent predicted forced vital capacity (FVC%) of 10% or greater or death during the 52-week treatment period. Key secondary endpoints included change in absolute and FVC% over 52 weeks. Findings. The trial was stopped early due to slow recruitment and soon after the shutdown of clinical trials as a consequence of the coronavirus disease 2019 (COVID-19) pandemic. Data from 123 patients enrolled were analyzed. The primary endpoint was met by 11.1% on pirfenidone vs. 15% on placebo [OR=0.67 (0.22, 2.03), p=0.48]. Subjects receiving pirfenidone had a slower rate of decline in lung function as measured by estimated annual change in FVC(ml) (-66 vs. -146, p=0.0082) and FVC(%) (-1.02 vs. -3.21, p=0.0028). This effect on decline was also seen when analyzed within participants with baseline usual interstitial pneumonia (UIP) pattern on HRCT (FVC(ml) (-43 vs. -169, p=0.0014) and FVC% (-0.2 vs. -3.81, p=0.0002)). There was no significant difference in the rate of treatment-emergent serious adverse events. Interpretation Due to early termination of the study, results should be interpreted with caution. Despite being underpowered to evaluate the primary endpoint, pirfenidone slowed the rate of decline of FVC over time in subjects with RA-ILD. Safety in patients with RA-ILD was similar to that seen in other pirfenidone trials.

Rheumatoid arthritis (RA) is the most common of the connective tissue diseases (CTD), affecting up to 0.75% of the United States (US) population, with increasing prevalence (1) . The global prevalence of RA is 0.24% (or 16 million people), ranking as the 42 nd highest contributor to global disability (2) . In the US alone, the annual excess health cost related to RA is estimated at $19.3 billion (3). (4) . While any lung compartment may be involved (5) , interstitial lung disease (ILD) is the leading cause of excess morbidity and mortality amongst pulmonary complications in RA. The prevalence of RA-related ILD (RA-ILD) ranges from 19 to 63% (6) , with a lifetime risk in any one patient of 7.7% (4) . Usual interstitial pneumonia (UIP) pattern on Computed Tomography (CT) and pathology is the most common manifestation of RA-ILD and is associated with poor prognosis similar to patients with idiopathic pulmonary fibrosis (IPF). This distinguishes RA-ILD from many other forms of CTD-ILD, where non-specific interstitial pneumonia (NSIP) and organizing pneumonia (OP) are typically found. This similarity between RA-ILD and IPF has led to speculation that therapeutic agents with efficacy in IPF might also be beneficial in RA-ILD. Although scientific advances in the last decade have led to significant improvements in the control of the joint disease in RA, there is no known treatment for RA-ILD and thus the need for an efficacious treatment for RA-ILD is unmet to date.

Respiratory system involvement is common in RA and leads to increased morbidity and mortality Pirfenidone is a therapeutic compound with both anti-inflammatory and anti-fibrotic properties. It is effective in several animal models of fibrosis (7) and has been studied in 15 controlled or uncontrolled clinical trials in human subjects with pulmonary fibrosis (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . It has been approved in many countries for the treatment of patients with IPF based on phase-3 clinical trial results (14) . In the Treatment for Rheumatoid Arthritis and Interstitial Lung Disease 1 (TRAIL1) trial, we examined the effect of pirfenidone on the progression of lung disease in patients with RA and fibrotic ILD.

The TRAIL1 study was a multinational randomized, double-blind, placebo-controlled, phase 2 study of the safety, tolerability, and efficacy of pirfenidone in patients with RA-ILD conducted in 33 sites in 4 countries (Australia, Canada, United Kingdom, and the US) (23) . The trial was conducted in accordance with the trial protocol (available with the full text of this article) and the Harmonized Tripartite Guideline for Good Clinical Practice from the International Conference on Harmonization, and in compliance with the ethical principles of the Declaration of Helsinki. All participants provided written consent before entry into the study. Safety and regulatory oversight was conducted under the direction of a Data and Safety and Monitoring Board (DSMB), which was composed of individuals with expertise in RA-ILD, the study drugs and clinical trials research. At the completion of the study, authors had full access to the data for analysis.

Recruitment began May 2017 and ended March 2020. Eligible patients were aged 18 to 85 years who were diagnosed with RA based on the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria (24) and ILD based on high-resolution computed tomography (HRCT) and, when available, surgical lung biopsy. Screening HRCT scans required the presence of fibrotic abnormality affecting more than 10% of the lung parenchyma, with or without traction All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 1, 2022. ; https://doi.org/10.1101/2022.04.01.22273270 doi: medRxiv preprint bronchiectasis or honeycombing and with no evidence or suspicion of an alternate diagnosis, as confirmed by a centrally adjudicated expert read. Patients were required to have a percent predicted forced vital capacity (FVC%) 40 and percent predicted diffusing capacity of the lung for carbon monoxide (DLCO%) 30 at screening as well as 10% relative change in pre-bronchodilator FVC between the screening (Visit 1) and baseline study visits (Visit 2). Exclusion from participation included patients who had the introduction or dose alteration of corticosteroids or any cytotoxic, immunosuppressive, cytokine-modulating or receptor antagonist agent specifically for the management of pulmonary manifestations of RA within 3 months of screening were excluded. In addition, patients with other lung manifestations of RA and those with a secondary CTD or overlap syndrome were excluded. All prohibited therapies (e.g., potent inhibitors or inducers of CYP1A2, etc.) must have been discontinued for at least 28 days before the start of screening (a comprehensive list of inclusion and exclusion criteria is provided in the Supplementary Appendix D).

After written consent was obtained, eligible patients were randomized in a 1:1 ratio to receive oral pirfenidone (at a dose of 2,403 mg per day in divided doses) or placebo for 52 weeks (Figure 1) . The study drug was titrated to full dose over a 14-day period and patients were maintained on study treatment for the duration of the trial (52 weeks).

There were a total of 11 in-person visits, and the primary efficacy evaluation was conducted at week 52. Patients underwent spirometry and completed health-related quality of life (HrQOL) questionnaires at weeks 0, 13, 26, 39 and 52. HRCT scans were obtained at the beginning and end of the study period. All HRCT scans underwent a centralized interpretation to determine eligibility as well as pattern of ILD, and spirometry was centrally reviewed for adequacy and repeatability according to the American Thoracic Society criteria (25) . The study protocol was approved by the institutional review board or ethics committee at each participating center and a DSMB maintained oversight throughout the trial. Details are provided in the Supplementary Appendix C.

The primary endpoint of the study was the incidence of the composite endpoint of decline in percent predicted FVC of 10% or greater, or death, during the 52-week study period. Key secondary endpoints included changes in absolute and percent predicted Other pre-specified secondary endpoints include the rate of FVC change, time to the composite endpoint of 10% change in FVC or death, health outcomes (hospitalizations, mortality, adjudicated exacerbations, and transplant) and safety (adverse events (AEs) and serious adverse events (SAEs)). The incidence, type and severity of treatmentemergent adverse events were recorded and summarized according to primary System All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

The planned sample size was 270 participants randomized with equal probability to pirfenidone or placebo, to determine the outcomes of 254 participants with complete study data, providing at least 85% power to demonstrate the treatment arm difference for the primary endpoint. Enrollment was interrupted by the COVID-19 pandemic in March 2020. After centers were closed for approximately three months, and review of study feasibility with the DSMB, enrollment ended, and the study participants were followed per protocol. The final sample size was 123 participants with the last participant visit on April 7, 2021.

The primary efficacy outcome was the composite endpoint of a decline from baseline in FVC% of 10% or greater or death, analyzed using intention to treat principles. The screening spirometry values that met established quality criteria served as baseline randomization values and were performed before and after bronchodilator administration. The treatment arms were compared using a logistic regression model. Treatment arm was the main independent fixed effect, and pre-specified covariates included baseline percent predicted FVC and HRCT predominant pattern (UIP vs. other pattern). The alpha level for the primary endpoint was 0.05, two-sided, according to the trial design with no interim analyses. The adjusted odds ratio with 95% confidence interval was used to quantify the treatment effect for pirfenidone relative to placebo, with an odds ratio less than 1.0 indicating that pirfenidone is protective. A sensitivity analysis to assess the robustness of the primary analysis was performed using an adjusted perprotocol population with an expanded definition of treatment compliance.

Binary secondary endpoints, including annual rate of FVC decline in abslolute values (ml and % predicted) were analyzed using a logistic regression model similar to the primary endpoint analysis. Continuous, longitudinal secondary endpoints were analyzed using a restricted maximum likelihood-based repeated measures approach with random intercept. The longitudinal model included the effects of treatment arm, visit (actual weeks since randomization) and treatment arm-by-visit interaction, with the baseline value as covariate. The Kenward-Roger approximation was used and the covariance structure converging to the best fit by Akaike's information criterion was selected. The analysis included all measurements obtained over the study period. The primary treatment comparison of slopes was assessed through the treatment-by-visit interaction.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 1, 2022. ; https://doi.org/10.1101/2022.04.01.22273270 doi: medRxiv preprint Time-to-event secondary outcomes were analyzed using mixed effect proportional hazards regression modelling with treatment arm as main effect, network (US, UK, Canada, Australia) as random effect, and with baseline HRCT pattern (UIP vs. other patterns) as covariate. For time-to-event analyses involving spirometry, the baseline value was also a covariate. The censoring date was the earlier of the end of study period date or the date the participant was last observed without the event. Breslow's method for handling ties was used, and Kaplan Meier plots and Schoenfeld residuals showed that the proportion hazards assumption was reasonable. The adjusted hazard ratio with 95% confidence interval was used to quantify the treatment effect for pirfenidone relative to placebo. For endpoints that indicate a decline in function, a hazard ratio less than 1.0 indicates that pirfenidone is protective.

Subgroup analyses related to the HRCT predominant pattern were not pre-specified.

These were performed after observing a randomization imbalance with respect to the HRCT pattern, to generate hypotheses, and to allow comparison with relevant previously published trials that reported results for participants with UIP (27) . Results related to the HRCT pattern subgroups were derived from full models described above, with the addition of a treatment by visit by HRCT pattern (UIP vs. other pattern) interaction term.

Exploratory endpoints, patient reported outcomes, adverse events, and variables related to administrative data were analyzed using chi square test for binary data or All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wilcoxon-Mann-Whitney test for continuous data. The as-treated population was used for adverse events.

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

From May 2017 to March 2020, a total of 123 patients (63 in the pirfenidone group and 60 in the placebo group) were randomized (Figure 2) . The study was terminated early due to slow enrollment and the sudden shutdown of routine clinical and research operational activities as a consequence of the global coronavirus disease 2019 (COVID- 19) pandemic. Despite this abrupt cessation, all enrolled subjects completed the trial and there was no imputed data. With the exception of a higher percentage of subjects with a UIP pattern on HRCT in the placebo group, the demographics and baseline characteristics were similar and are summarized in Table 1 . The majority of patients were male (60.3% and 60.5% in the pirfenidone and placebo groups, respectively), in their seventh decade of life (mean age of 66.6 and 68.1, respectively) and white (88.9% and 93.3%, respectively). The mean baseline percent predicted FVC and DLCO were 69.4% and 50% in the pirfenidone group and 70.4% and 47.6% in the placebo group.

The mean CT extent of fibrosis was 20.8% and 24.2% respectively and the majority of All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 1, 2022. ; https://doi.org/10.1101/2022.04.01.22273270 doi: medRxiv preprint patients had a UIP pattern on HRCT (54% and 78.3% in the pirfenidone and placebo groups, respectively). Among the patients who received at least one dose of study medication, 82.5% in the pirfenidone group and 85% in the placebo group completed the study. The duration of exposure to the study drug in the pirfenidone and placebo groups were similar (median (IQR) of 51.1 (19.1, 52. 3) weeks and 51.4 (38.5, 52.2) weeks respectively) and the most frequent reasons for premature discontinuation of study drug were death and loss to follow-up (a total of 5 patients each in the intent-totreat population).

There was no significant difference in patients who reached the primary, composite endpoint of a decline from baseline in percent predicted FVC of 10% or greater or death, analyzed using intention to treat principles (11.1% on pirfenidone vs. 15 

In analysis of other secondary endpoints, the groups were similar with regards to the decline in percent predicted FVC by 10% or greater (7.9% vs. 11.7%, OR 0.52 (CI All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Adverse events are summarized in Table 3 . Treatment-emergent adverse events were seen in 100% of subjects on pirfenidone and 93.3% of subjects on placebo (p=0.0387).

Of these, adverse events felt to be related to treatment were reported more frequently in the pirfenidone group (43.6% vs 30.0%, p<0.1210). The most frequent adverse events, analyzed in the as-treated population, were nausea, fatigue, and diarrhea. These adverse events were generally mild and not clinically significant.

There was no difference between treatment arms in the number of treatment-related serious adverse events. Adverse events leading to the discontinuation of study drug occurred more frequently in those on pirfenidone (24% vs. 10%, p=0.0379). There was a total of 5 deaths (2 in the pirfenidone group and 3 in the placebo group), none of which were felt to be secondary to study drug. One of the 5 deaths was felt to be secondary to RA-ILD. There were no new safety signals identified. When analyses were limited to subjects on background therapy for RA (anti-inflammatories, TNF agents and rituximab), there was no difference between treatment arms in adverse events and serious adverse events (see Supplementary Appendix Table S2 ). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

In the TRAIL1 study we sought to investigate the safety and efficacy of pirfenidone in subjects with RA and fibrotic ILD. The trial was unfortunately aborted as the consequence of the global pandemic and anticipated failure to enroll the planned sample size and was therefore underpowered to evaluate the primary endpoint and draw meaningful conclusion. However, pre-specified secondary endpoints revealed a reduction in the decline in FVC over 52 weeks in those patients on pirfenidone relative to placebo. Though not statistically significant, differences in other secondary endpoints such as categorical decline in FVC%, frequency of progressive disease, change in the Dyspnea-12 and hospitalizations from a respiratory cause all favored pirfenidone. The magnitude of effect of pirfenidone on FVC decline in RA-ILD was similar to that seen in IPF and non-IPF progressive fibrotic ILDs in the ASCEND,INBUILD, pirfenidone in progressive fibrosing unclassifiable ILD and RELIEF trials (14, 28, 29) . Importantly, there were no new safety signals identified and treatment was well tolerated.

Recruitment for the TRAIL1 trial was challenging. Acknowledging that we were behind in recruitment prior to the COVID-19 pandemic, the abrupt shutdown of routine clinical and research activities as a consequence of the pandemic, and prioritization of the need to attend to management of COVID-19 patients at all centers worldwide led to the decision with input from the DSMB to terminate further enrollment. Power calculations determined that a sample size of 270 participants were needed to demonstrate the All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 1, 2022. ; https://doi.org/10.1101/2022.04.01.22273270 doi: medRxiv preprint treatment arm difference for the primary endpoint. Recruitment was terminated at 123 participants and all subjects finished the trial with no data imputation. Despite enrolling less than half of the originally planned cohort, pirfenidone reduced the FVC decline in all subjects by 55% and by 75% in those with a UIP-pattern of fibrosis.

Limited data suggest the influence of ILD on quality of life in those with RA is substantial, with patients scoring the same or worse on quality-of-life measures as those with IPF, a progressive fatal fibrosing ILD (30) . RA-ILD is a progressive disease; 60%

show radiographic progression over an 18-month period (31). ILD contributes to mortality in 7 to 9% of patients with RA (32) and patients with RA-ILD have an average lifespan of 2.6 years compared to 10 years in age-matched RA patients without ILD (4).

UIP is the most common radiographic pattern of lung injury (33) which is associated with a worse outcome (34) (35) (36) . In addition to its impact on patients, the burden of RA-ILD on the healthcare system is significant. The presence of ILD leads to an additional estimated 5-year cost of US $173,000 per patient (37) .

RA-ILD holds many similarities to IPF, with shared risk factors of male sex, older age and history of smoking (6, 38) . The HRCT appearance of UIP in RA and IPF is frequently indistinguishable. Other notable similarities include overlapping serum biomarker profiles (e.g., Krebs von den Lungen-6 (KL-6 (39, 40)), shared genetic risk factors (MUC5B and telomerase mutations (41) (42) (43) (44) ) and serologic evidence of autoimmunity (45) . RA-UIP and IPF have previously been shown to confer a similar poor prognosis (35, 36) though more recent studies have suggested a better prognosis All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 1, 2022. ; https://doi.org/10.1101/2022.04.01.22273270 doi: medRxiv preprint in RA-ILD (46) . These similarities and the proven benefit of pirfenidone on IPF (14) and other fibrotic ILDs that progress despite therapy (28) The effect of treatment with pirfenidone on the decline in FVC was more pronounced in those with a UIP pattern on HRCT (for the overall population, 11.1% in the treated group vs. 15% in the overall population reached the primary endpoint, compared to 8.8% vs. 14.9% in those with a UIP pattern on HRCT). Of the 16 participants who died or were hospitalized, 14 had a UIP pattern on imaging. Though the post-hoc nature of this analysis limits generalizability, these findings suggest that the pattern of fibrosis All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 1, 2022. ; https://doi.org/10.1101/2022.04.01.22273270 doi: medRxiv preprint could have therapeutic and prognostic significance above that provided by extent of fibrosis and deserves further study.

Treatment with pirfenidone was safe and well tolerated. Side effects were similar to those seen in other studies of pirfenidone in patients with ILD (14, 29) . The most common side effect was nausea, seen in half of patients on pirfenidone. Though the number of serious adverse events were lower in our study compared to ASCEND (14.5% vs. 18.7% respectively), subjects with RA-ILD had a higher rate of study-drug discontinuation (24.2% in TRAIL1 vs. 14.4% in ASCEND). As opposed to IPF, patients with RA-ILD have multi-system disease and are often on disease-modifying antirheumatic drugs (DMARDs) with their own side effect profile. When adverse and severe adverse events were analyzed in those on background agents for RA, no differences were noted between pirfenidone and placebo. The ability of pirfenidone to be added to background DMARD therapy for patients with RA in a safe and tolerable fashion is a significant finding of our study.

In spite of the positive finding of a slower decline in FVC in patients treated with pirfenidone, and acknowledging the early termination of the trial, we surface the following limitations: 1) due to early termination, we failed to meet the primary endpoint and results should be interpreted with care, 2) selection bias with an inclusion criteria of least 10% fibrosis on HRCT and an unknown applicability of our findings to patients with less fibrosis on HRCT and finally, 3) there were more patients with UIP in the placebo All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 1, 2022. ; https://doi.org/10.1101/2022.04.01.22273270 doi: medRxiv preprint arm of our trial though UIP pattern was used as a pre-established covariate in our analyses.

In summary, we present results from the first randomized placebo-controlled trial conducted exclusively in subjects with RA-ILD. We were forced to terminate the trial due to unforeseen circumstances that included the abrupt consequences of the COVID-19 pandemic and were underpowered to meet our primary endpoint. However, the use of pirfenidone was associated with a slower rate of FVC% decline in patients with RA-ILD compared to placebo and the totality of the evidence suggests that pirfenidone is effective in the treatment of RA-ILD. Treatment was well tolerated despite background RA-related therapy and no new safety signals were identified. In addition, we identified a subgroup of RA-ILD patients at risk for significant progression over time. UIP is the most common radiographic pattern seen in patients with RA-ILD and our data suggest they have a faster progression and may have a more robust response to therapy. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 1, 2022. ; 10.9 ± 4.4

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Abbreviations: FVC=forced vital capacity, DLCO=diffusing capacity for carbon monoxide, HRCT=highresolution computed tomography, SD=standard deviation, UIP=usual interstitial pneumonia, NSIP=nonspecific interstitial pneumonia, LIP=lymphocytic interstitial pneumonia Data are N (%) or mean and SD unless otherwise specified. Percentages are 100*n/N All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 1, 2022. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 1, 2022. 

Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases

The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study

Societal cost of rheumatoid arthritis patients in the US

Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study

Rheumatoid lung disease

The Epidemiology of Rheumatoid Arthritis-Associated Lung Disease

Antifibrotic activities of pirfenidone in animal models

Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis

Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study

Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome

Double-blind, placebocontrolled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

Pirfenidone in idiopathic pulmonary fibrosis

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients

e1600. Epub 2015/10/27

Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis

Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis

Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Epub 2016/05/11

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial

A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study)

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)

The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease

Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

Standardisation of spirometry

CTD-ILD) -Report from OMERACT CTD-ILD Working Group

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) -a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease

Rheumatoid arthritis-interstitial lung disease-associated mortality

Rheumatoid arthritisrelated lung diseases: CT findings

Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease

Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes

Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD)

Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality

Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement

Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease

Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis

MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease

A common MUC5B promoter polymorphism and pulmonary fibrosis

Telomerase mutations in families with idiopathic pulmonary fibrosis

Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis

IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis

High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis

Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality

Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATOID ARTHRITIS (RA-ILD) IN THE INBUILD TRIAL

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder